The World Health Organization (WHO) has issued a conditional recommendation against the use of Remdesivir in hospitalized patients, regardless of disease severity, as there is currently no evidence that remdesivir improves survival and other outcomes in these patients.This was reported by the press service of the WHO.
"The evidence suggested no important effect on mortality, need for mechanical ventilation, time to clinical improvement, and other patient-important outcomes," the WHO stressed.
Work on this began on 15 October when the WHO Solidarity Trial published its interim results. Data reviewed by the panel included results from this trial, as well as 3 other randomized controlled trials. In all, data from over 7000 patients across the 4 trials were considered.
The guidelines were developed in collaboration with the non-profit Magic Evidence Ecosystem Foundation (MAGIC), which provided methodologic support. The guidelines are an innovation, matching scientific standards with the speed required to respond to an ongoing pandemic.
As we reported earlier, on May 2, 2020, Remdesivir was approved in the United States for the emergency treatment of coronavirus disease.
The drug is included in the Ukrainian protocol for treating coronavirus: the Ministry of Health have already ordered an expensive drug. On November 19, Deputy Health Minister Lyashko said that "the drug has already been purchased and is being shipped to Ukraine."